JP2009541270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541270A5 JP2009541270A5 JP2009515889A JP2009515889A JP2009541270A5 JP 2009541270 A5 JP2009541270 A5 JP 2009541270A5 JP 2009515889 A JP2009515889 A JP 2009515889A JP 2009515889 A JP2009515889 A JP 2009515889A JP 2009541270 A5 JP2009541270 A5 JP 2009541270A5
- Authority
- JP
- Japan
- Prior art keywords
- propyl
- phenyl
- group
- oxo
- methylpropanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- XENZDXWACHXFJS-UHFFFAOYSA-N 2-[4-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-3-oxopropyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C(=CC(=CC=2)C(F)(F)F)F)=C1 XENZDXWACHXFJS-UHFFFAOYSA-N 0.000 claims 2
- -1 4- (trifluoromethoxy) phenyl Chemical group 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000924 antiasthmatic agent Substances 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940127088 antihypertensive drug Drugs 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- VEAFKIYNHVBNIP-UHFFFAOYSA-N 1,3-Diphenylpropane Chemical class C=1C=CC=CC=1CCCC1=CC=CC=C1 VEAFKIYNHVBNIP-UHFFFAOYSA-N 0.000 claims 1
- YRTKSVYRJXYVCW-UHFFFAOYSA-N 2-[2,6-dimethoxy-4-[3-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound COC1=C(OC(C)(C)C(O)=O)C(OC)=CC(CCC(=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 YRTKSVYRJXYVCW-UHFFFAOYSA-N 0.000 claims 1
- RRUNVFABJGMXLW-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-(pyridin-3-ylmethoxy)-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(OCC=2C=NC=CC=2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 RRUNVFABJGMXLW-UHFFFAOYSA-N 0.000 claims 1
- DDEUNSGQVIQYDE-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-[2-methyl-4-(2,2,2-trifluoroethoxy)phenyl]-3-oxopropyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C(=CC(OCC(F)(F)F)=CC=2)C)=C1 DDEUNSGQVIQYDE-UHFFFAOYSA-N 0.000 claims 1
- RWFGEIAPBPKTPW-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[2-propan-2-yloxy-4-(trifluoromethyl)phenyl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound CC(C)OC1=CC(C(F)(F)F)=CC=C1C(=O)CCC1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 RWFGEIAPBPKTPW-UHFFFAOYSA-N 0.000 claims 1
- YEUJJLZYCJUQBX-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[4-(2,2,2-trifluoroethoxy)phenyl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(OCC(F)(F)F)=CC=2)=C1 YEUJJLZYCJUQBX-UHFFFAOYSA-N 0.000 claims 1
- FDBFDHWDSZZJTM-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[4-(2,2,2-trifluoroethylsulfanyl)phenyl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(SCC(F)(F)F)=CC=2)=C1 FDBFDHWDSZZJTM-UHFFFAOYSA-N 0.000 claims 1
- WSQKEUFAAAVREJ-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[4-(3,3,3-trifluoropropoxy)phenyl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(OCCC(F)(F)F)=CC=2)=C1 WSQKEUFAAAVREJ-UHFFFAOYSA-N 0.000 claims 1
- STHVVRDEILFYHO-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]-2,2-difluoroacetic acid Chemical compound CC1=C(OC(F)(F)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 STHVVRDEILFYHO-UHFFFAOYSA-N 0.000 claims 1
- SQRQBKDQFTVKCU-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]-2-methylpropanamide Chemical compound CC1=C(OC(C)(C)C(N)=O)C(C)=CC(CCC(=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 SQRQBKDQFTVKCU-UHFFFAOYSA-N 0.000 claims 1
- WRDCXILLMRMRBK-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 WRDCXILLMRMRBK-UHFFFAOYSA-N 0.000 claims 1
- HXDMXJNVVPMKJM-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]propanoic acid Chemical compound C1=C(C)C(OC(C)C(O)=O)=C(C)C=C1CCC(=O)C1=CC=C(OC(F)(F)F)C=C1 HXDMXJNVVPMKJM-UHFFFAOYSA-N 0.000 claims 1
- DRJCNJJQMRDUMO-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethyl)phenyl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 DRJCNJJQMRDUMO-UHFFFAOYSA-N 0.000 claims 1
- OUBZNZRLCZKBHH-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethylsulfanyl)phenyl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(SC(F)(F)F)=CC=2)=C1 OUBZNZRLCZKBHH-UHFFFAOYSA-N 0.000 claims 1
- GCPHEIPICDTSAY-UHFFFAOYSA-N 2-[2-methoxy-4-[3-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]phenyl]sulfanyl-2-methylpropanoic acid Chemical compound C1=C(SC(C)(C)C(O)=O)C(OC)=CC(CCC(=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 GCPHEIPICDTSAY-UHFFFAOYSA-N 0.000 claims 1
- CSMAUHWOPWAKBV-UHFFFAOYSA-N 2-[4-[3-(4-bromophenyl)-3-oxopropyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(Br)=CC=2)=C1 CSMAUHWOPWAKBV-UHFFFAOYSA-N 0.000 claims 1
- QZXNMBRZCTYBND-UHFFFAOYSA-N 2-[4-[3-(4-chloro-2-hydroxyphenyl)-3-oxopropyl]phenyl]sulfanyl-2-methylpropanoic acid Chemical compound C1=CC(SC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(Cl)C=C1O QZXNMBRZCTYBND-UHFFFAOYSA-N 0.000 claims 1
- LECIVISKMBPGKY-UHFFFAOYSA-N 2-[4-[3-(4-chloro-2-methylsulfanylphenyl)-3-oxopropyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CSC1=CC(Cl)=CC=C1C(=O)CCC1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 LECIVISKMBPGKY-UHFFFAOYSA-N 0.000 claims 1
- JNQGRNMSUIFOPP-UHFFFAOYSA-N 2-[4-[3-[(4-iodophenyl)methoxy]-3-[4-(trifluoromethoxy)phenyl]propyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(OCC=2C=CC(I)=CC=2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 JNQGRNMSUIFOPP-UHFFFAOYSA-N 0.000 claims 1
- NLIIFQNUEMXJPJ-UHFFFAOYSA-N 2-[4-[3-[2,4-bis(trifluoromethyl)phenyl]-3-oxopropyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C(=CC(=CC=2)C(F)(F)F)C(F)(F)F)=C1 NLIIFQNUEMXJPJ-UHFFFAOYSA-N 0.000 claims 1
- FYHMOTMIFBSTRV-UHFFFAOYSA-N 2-[4-[3-[2-fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-3-oxopropyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C(=CC(OCC(F)(F)F)=CC=2)F)=C1 FYHMOTMIFBSTRV-UHFFFAOYSA-N 0.000 claims 1
- RFBBRVVKDWRRPJ-UHFFFAOYSA-N 2-[4-[3-[2-fluoro-4-(trifluoromethyl)phenyl]-3-oxopropyl]phenyl]sulfanyl-2-methylpropanoic acid Chemical compound C1=CC(SC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C(F)(F)F)C=C1F RFBBRVVKDWRRPJ-UHFFFAOYSA-N 0.000 claims 1
- RHRUJFONHSLUEN-UHFFFAOYSA-N 2-[4-[3-[2-hydroxy-4-(trifluoromethyl)phenyl]-3-oxopropyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C(=CC(=CC=2)C(F)(F)F)O)=C1 RHRUJFONHSLUEN-UHFFFAOYSA-N 0.000 claims 1
- WXYGEFYOYADWQW-UHFFFAOYSA-N 2-[4-[3-[2-methoxy-4-(2,2,2-trifluoroethoxy)phenyl]-3-oxopropyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound COC1=CC(OCC(F)(F)F)=CC=C1C(=O)CCC1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 WXYGEFYOYADWQW-UHFFFAOYSA-N 0.000 claims 1
- VWGKHNZTCXEQLW-UHFFFAOYSA-N 2-[4-[3-[2-methoxy-4-(trifluoromethyl)phenyl]-3-oxopropyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound COC1=CC(C(F)(F)F)=CC=C1C(=O)CCC1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 VWGKHNZTCXEQLW-UHFFFAOYSA-N 0.000 claims 1
- QAMSIILIVPBGHQ-UHFFFAOYSA-N 2-[4-[3-hydroxy-3-[4-(trifluoromethoxy)phenyl]propyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 QAMSIILIVPBGHQ-UHFFFAOYSA-N 0.000 claims 1
- CSJWKNVMZLJMSK-UHFFFAOYSA-N 2-[4-[3-hydroxy-3-[4-(trifluoromethylsulfanyl)phenyl]propyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(O)C=2C=CC(SC(F)(F)F)=CC=2)=C1 CSJWKNVMZLJMSK-UHFFFAOYSA-N 0.000 claims 1
- CRXGOEILHSWZMC-UHFFFAOYSA-N 2-[4-[3-methoxyimino-3-[4-(trifluoromethoxy)phenyl]propyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound C=1C=C(OC(F)(F)F)C=CC=1C(=NOC)CCC1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 CRXGOEILHSWZMC-UHFFFAOYSA-N 0.000 claims 1
- VBWPERKZJXMVHC-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[3-oxo-3-[4-(3,3,3-trifluoropropoxy)phenyl]propyl]phenoxy]propanoic acid Chemical compound C1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(OCCC(F)(F)F)=CC=2)=C1 VBWPERKZJXMVHC-UHFFFAOYSA-N 0.000 claims 1
- BHWWMQBVMLKEQK-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[3-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]propanoic acid Chemical compound C1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 BHWWMQBVMLKEQK-UHFFFAOYSA-N 0.000 claims 1
- GSRWDZHYAAIPQD-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[3-oxo-3-[4-(trifluoromethylsulfanyl)phenyl]propyl]phenoxy]propanoic acid Chemical compound C1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(SC(F)(F)F)=CC=2)=C1 GSRWDZHYAAIPQD-UHFFFAOYSA-N 0.000 claims 1
- NMKVWTMTUQHVIB-UHFFFAOYSA-N 2-methyl-2-[3-[3-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]propanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC(CCC(=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 NMKVWTMTUQHVIB-UHFFFAOYSA-N 0.000 claims 1
- LUVXSAKVSSYDST-UHFFFAOYSA-N 4-[2,6-dimethyl-4-[3-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]-2,2-dimethylbutanoic acid Chemical compound CC1=C(OCCC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2C=CC(OC(F)(F)F)=CC=2)=C1 LUVXSAKVSSYDST-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- KARXHVZRISNXON-UHFFFAOYSA-N CC1=C(OC(C(=O)O)(CC)C(C)C)C(=CC(=C1)CCC(C1=CC=C(C=C1)OC(F)(F)F)=O)C Chemical compound CC1=C(OC(C(=O)O)(CC)C(C)C)C(=CC(=C1)CCC(C1=CC=C(C=C1)OC(F)(F)F)=O)C KARXHVZRISNXON-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000002253 anti-ischaemic effect Effects 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000023852 carbohydrate metabolic process Effects 0.000 claims 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000003544 oxime group Chemical group 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0605540A FR2902789A1 (fr) | 2006-06-21 | 2006-06-21 | Derives de 1,3-diphenylpropane substitues, preparations et utilisations |
| FR06/05540 | 2006-06-21 | ||
| PCT/EP2007/056225 WO2007147880A1 (fr) | 2006-06-21 | 2007-06-21 | Derives de 1,3-diphenylpropane substitues, preparations et utilisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009541270A JP2009541270A (ja) | 2009-11-26 |
| JP2009541270A5 true JP2009541270A5 (enExample) | 2010-07-15 |
| JP5350231B2 JP5350231B2 (ja) | 2013-11-27 |
Family
ID=37845179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515889A Expired - Fee Related JP5350231B2 (ja) | 2006-06-21 | 2007-06-21 | 置換された１，３−ジフェニルプロパン誘導体、その製造および使用 |
| JP2009515888A Active JP5350230B2 (ja) | 2006-06-21 | 2007-06-21 | 置換された１，３−ジフェニルプロパン誘導体、その製造および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515888A Active JP5350230B2 (ja) | 2006-06-21 | 2007-06-21 | 置換された１，３−ジフェニルプロパン誘導体、その製造および使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8188148B2 (enExample) |
| EP (2) | EP2046715B1 (enExample) |
| JP (2) | JP5350231B2 (enExample) |
| KR (2) | KR101416257B1 (enExample) |
| CN (3) | CN101506138B (enExample) |
| AU (2) | AU2007262939B2 (enExample) |
| BR (1) | BRPI0713600B1 (enExample) |
| CA (2) | CA2655643C (enExample) |
| CY (2) | CY1115082T1 (enExample) |
| DK (2) | DK2046716T3 (enExample) |
| EA (1) | EA018437B1 (enExample) |
| ES (2) | ES2434071T3 (enExample) |
| FR (1) | FR2902789A1 (enExample) |
| IL (2) | IL196057A (enExample) |
| MX (1) | MX2008016239A (enExample) |
| NO (1) | NO341866B1 (enExample) |
| NZ (1) | NZ573674A (enExample) |
| PL (2) | PL2046716T3 (enExample) |
| PT (2) | PT2046716E (enExample) |
| SI (2) | SI2046716T1 (enExample) |
| WO (2) | WO2007147880A1 (enExample) |
| ZA (1) | ZA200810709B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2902789A1 (fr) * | 2006-06-21 | 2007-12-28 | Genfit Sa | Derives de 1,3-diphenylpropane substitues, preparations et utilisations |
| FR2917084B1 (fr) * | 2007-06-05 | 2009-07-17 | Galderma Res & Dev | Nouveaux derives d'acide 3-phenyl propanoique activateurs des recpteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques. |
| US10722575B2 (en) | 2009-11-26 | 2020-07-28 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| US9221751B2 (en) | 2009-11-26 | 2015-12-29 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| ES2441665T3 (es) * | 2009-11-26 | 2014-02-05 | Genfit | Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos |
| WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
| CA2800337C (en) | 2010-05-17 | 2019-01-29 | Genfit | Improved preparation of chalcone derivatives |
| MX2013000391A (es) * | 2010-07-12 | 2013-03-08 | Hoffmann La Roche | 1-hidroxiimino-3-fenil-propanos. |
| EP2780330B1 (en) * | 2011-11-14 | 2016-01-06 | F.Hoffmann-La Roche Ag | 1-pyridazinyl-hydroxyimino- 3- phenyl- propanes as gpbar1 agonists |
| EA031899B9 (ru) * | 2011-12-28 | 2019-08-30 | Жанфит | Производные 1,3-дифенилпропана, их получение и применение |
| US10442761B2 (en) | 2016-02-16 | 2019-10-15 | Concert Pharmaceuticals, Inc. | Deuterated GFT-505 |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| IT201600098338A1 (it) * | 2016-09-30 | 2018-03-30 | Univ Degli Studi Padova | Composti 1-fenilpropanone e loro impiego |
| RU186145U1 (ru) * | 2018-08-08 | 2019-01-11 | Общество с ограниченной ответственностью "Научно-производственное объединение "Центротех" (ООО "НПО "Центротех") | Каркас виброрамы вибросита |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| KR20220140762A (ko) | 2020-02-10 | 2022-10-18 | 장피트 | 엘라피브라노에 의한 원발 담즙성 담관염의 치료 |
| WO2021169769A1 (zh) * | 2020-02-28 | 2021-09-02 | 四川科伦博泰生物医药股份有限公司 | 芳香族化合物及其药物组合物和用途 |
| MX2022014364A (es) * | 2020-05-18 | 2022-12-15 | Genfit | Elafibranor para el tratamiento de la colangitis esclerosante primaria. |
| CN115884765A (zh) | 2020-08-26 | 2023-03-31 | 基恩菲特公司 | 用于治疗原发性胆汁性胆管炎的组合物和方法 |
| US20240216312A1 (en) | 2021-05-11 | 2024-07-04 | Genfit | Ppar-agonists for use in the treatment of liver failure |
| WO2022238448A1 (en) | 2021-05-11 | 2022-11-17 | Genfit | Elafibranor derivatives agonists of ppar for use in the treatment of sepsis |
| TW202527918A (zh) | 2023-10-13 | 2025-07-16 | 法商Ｇｅｎｆｉｔ公司 | 原發性膽汁性膽管炎之治療方法 |
| CN122055145A (zh) | 2023-10-25 | 2026-05-15 | 基恩菲特公司 | 用于治疗原发性胆汁性胆管炎的埃拉菲布拉诺 |
| WO2025215081A1 (en) | 2024-04-09 | 2025-10-16 | Genfit | Elafibranor for use for long-term treatment of primary biliary cholangitis |
| WO2026047132A1 (en) | 2024-08-29 | 2026-03-05 | Genfit | Treatment of advanced primary biliary cholangitis |
| CN119490528A (zh) * | 2025-01-17 | 2025-02-21 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 一种HSP90α选择性抑制剂及其合成方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2149070C3 (de) | 1971-10-01 | 1978-03-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel |
| HU200591B (en) * | 1986-07-11 | 1990-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds |
| DE4121849A1 (de) * | 1991-07-02 | 1993-01-14 | Rhone Poulenc Rorer Gmbh | (4-((omega)-arylalkyl)-phenyl)alkansaeuren, ihre salze und/oder ihre derivate |
| DE4327365A1 (de) * | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung |
| HRP20010795A2 (en) * | 1999-04-28 | 2003-02-28 | Aventis Pharma Gmbh | Di-aryl acid derivatives as ppar receptor ligands |
| DE19933421A1 (de) * | 1999-07-16 | 2001-01-25 | Gruenenthal Gmbh | 2-Benzyl-3-dimethylamino-1-phenyl-propanderi- vate |
| FR2841900B1 (fr) | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| RU2006112342A (ru) * | 2003-10-28 | 2007-12-10 | Д-р Редди`с Лабораторис Лтд (IN) | Новые соединения и их использование в медицине, способ их получения и содержащие их фармацетические композиции |
| MY147518A (en) * | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| FR2902789A1 (fr) | 2006-06-21 | 2007-12-28 | Genfit Sa | Derives de 1,3-diphenylpropane substitues, preparations et utilisations |
-
2006
- 2006-06-21 FR FR0605540A patent/FR2902789A1/fr not_active Withdrawn
-
2007
- 2007-06-21 ES ES07786798T patent/ES2434071T3/es active Active
- 2007-06-21 ES ES07730296.6T patent/ES2466268T3/es active Active
- 2007-06-21 CN CN200780030962.XA patent/CN101506138B/zh active Active
- 2007-06-21 WO PCT/EP2007/056225 patent/WO2007147880A1/fr not_active Ceased
- 2007-06-21 DK DK07786798.4T patent/DK2046716T3/da active
- 2007-06-21 EA EA200900044A patent/EA018437B1/ru not_active IP Right Cessation
- 2007-06-21 DK DK07730296.6T patent/DK2046715T5/da active
- 2007-06-21 PT PT77867984T patent/PT2046716E/pt unknown
- 2007-06-21 WO PCT/EP2007/056224 patent/WO2007147879A1/fr not_active Ceased
- 2007-06-21 PL PL07786798T patent/PL2046716T3/pl unknown
- 2007-06-21 JP JP2009515889A patent/JP5350231B2/ja not_active Expired - Fee Related
- 2007-06-21 US US12/308,558 patent/US8188148B2/en not_active Expired - Fee Related
- 2007-06-21 KR KR1020097001318A patent/KR101416257B1/ko not_active Expired - Fee Related
- 2007-06-21 PT PT77302966T patent/PT2046715E/pt unknown
- 2007-06-21 EP EP07730296.6A patent/EP2046715B1/fr active Active
- 2007-06-21 CN CN201410016196.3A patent/CN104193660B/zh active Active
- 2007-06-21 CA CA2655643A patent/CA2655643C/fr active Active
- 2007-06-21 US US12/308,580 patent/US8258182B2/en active Active
- 2007-06-21 CA CA2655744A patent/CA2655744C/fr active Active
- 2007-06-21 SI SI200731347T patent/SI2046716T1/sl unknown
- 2007-06-21 MX MX2008016239A patent/MX2008016239A/es active IP Right Grant
- 2007-06-21 PL PL07730296T patent/PL2046715T3/pl unknown
- 2007-06-21 CN CN2007800310203A patent/CN101506139B/zh not_active Expired - Fee Related
- 2007-06-21 KR KR1020097001319A patent/KR101416262B1/ko active Active
- 2007-06-21 BR BRPI0713600-5A patent/BRPI0713600B1/pt not_active IP Right Cessation
- 2007-06-21 NZ NZ573674A patent/NZ573674A/en not_active IP Right Cessation
- 2007-06-21 AU AU2007262939A patent/AU2007262939B2/en not_active Ceased
- 2007-06-21 JP JP2009515888A patent/JP5350230B2/ja active Active
- 2007-06-21 AU AU2007262938A patent/AU2007262938B2/en active Active
- 2007-06-21 SI SI200731453T patent/SI2046715T1/sl unknown
- 2007-06-21 EP EP07786798.4A patent/EP2046716B1/fr active Active
-
2008
- 2008-12-18 IL IL196057A patent/IL196057A/en active IP Right Grant
- 2008-12-18 IL IL196071A patent/IL196071A0/en active IP Right Grant
- 2008-12-19 NO NO20085338A patent/NO341866B1/no not_active IP Right Cessation
- 2008-12-19 ZA ZA200810709A patent/ZA200810709B/xx unknown
-
2013
- 2013-10-30 CY CY20131100955T patent/CY1115082T1/el unknown
-
2014
- 2014-05-27 CY CY20141100379T patent/CY1115414T1/el unknown